XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.
|Videos|November 4, 2022
RSV, influenza, and COVID-19: Gearing up for the threat of a 'triple epidemic'
Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sits down to discuss the rising threat of a "triple epidemic" consisting of influenza, COVID-19, and RSV in children.
Advertisement
Contemporary Pediatrics® Editor-in-Chief Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sits down to discuss the recent surge in pediatric RSV hospitalizations and the rising threat of the "triple epidemic" consisting of influenza, COVID-1, and RSV in children.
Advertisement
Related to this article
Infliximab or steroids may be more effective than anakinra as adjunctive therapy for children with MIS-C who do not respond to IVIG.
This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
Five rapid developments — new mRNA flu vaccine, CDC director, ACIP/NVAC charters, a vaccine order, and an HHS RFI — roil the 2026 schedule.
Court fight over CDC 2026 childhood vaccine schedule shifts shots to shared decision-making; experts warn lower uptake for Hep A, B, flu, COVID.
New evidence supports influenza, COVID-19, and RSV immunizations for reducing severe respiratory illness and hospitalization.
The AAP's 2026-2027 policy recommends universal vaccination for infants 6-23 months and a risk-based single dose for children 2-18 years.
AAP guidance expands RSV immunization eligibility for children aged 8 through 19 months at high risk of severe disease.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
FDA approves levacetylleucine as first treatment for ataxia in ataxia-telangiectasia
3
FDA grants priority review to efzimfotase alfa for hypophosphatasia in patients aged 2 years and older
4
Atopic dermatitis linked to higher ADHD risk in children, with sleep disturbance emerging as key factor
5